Among 1001 subjects, 278 patients (27.8%) experienced at least 1 adverse event (AE) during 24 weeks of follow-up, 5 of those (0, 5%) were serious adverse events (SAEs) and 29 (2.9%) led to modification of dapagliflozin treatment.